Skip to main content
Equibles
RDY logo

RDY · Dr Reddys Laboratories Ltd

Track RDY — free

Use RDY with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RDY

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.18 +0.02 (+0.16%) At close · Aug 28
Rebalance outlook locked
Market Cap
$10.10B
Shares
832.99M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.18 Open$12.33 Day$12.12–12.33 52W close$11.38–15.38 Avg vol 30d2.7M Short int22.5M · 2.7% float · 8.8d Short vol55% Last earningsSep 30, 2025 DataNov 2024–Aug 2026

Raw chart and full-history price indicators begin at the captured split on Nov 5, 2024; bars on opposite sides are not compared.

Up next

FQ2-27 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Limited Quant / Vol Low
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −5%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +3%
trailing
6-month return −15%
trailing
YTD return −13%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $13 › 200d $14 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.70% of float · ▲ +7.8% MoM · 8.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
240 holders — mid 3-yr range
Squeeze score 57
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Low
Volatility 27%
annualized · 1-yr
Max drawdown −26%
past year
ATR 1.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2025
full fiscal
R&D investments as a percentage of sales 7% – 7.5%
full fiscal year
Normalized effective tax rate (ETR) 25%
Prior guidance period ended · from the Earnings Call filed Sep 30, 2024
SG&A as a percentage of sales · full fiscal 27.5% – 28%
R&D as a percentage of sales · full fiscal 8.5% – 9%
Normalized effective tax rate · the fiscal 25%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−5% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $13 › 200d $14 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.70% of float · ▲ +7.8% MoM · 8.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
240 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11 Now $12 · 20% Range high $15
vs 200-day avg -10% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RDY
Dr Reddys Laboratories Ltd
this stock
$10.10B -13.2% — — 2.7%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $57.59B +15.7% — — 0.1%
GALDY
Galderma Group AG/ADR
 $49.41B +2.2% — — 0.0%
HLN
Haleon plc
 $44.15B +0.0% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
240
% held
15.1%
Net QoQ
+5.1M sh
Top holder
Robeco Institutional Asse…
Held Float
View
Held by Funds
Fund positions
59
View
Short & Settlement
Short Interest Rising
Shares short
22.5M
Days to cover
8.8d
Change
+1.6M sh
View
Short Volume
Short vol %
55%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
4
Value
$47
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
36.9%
Week of
Jul 20, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 26, 2026
This year
83
View
Proposed Sales
Value
$5.4M
Shares
65.5K
Filed
Jul 29, 2024
View
Earnings & Events
Earnings Calls
Last call
Sep 30, 2025
View

Performance

Raw-price comparisons begin at the captured split on Nov 5, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
RDY +0.0% +2.8% -15.4% +2.8% -13.3%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -0.5% -0.2% -28.8% -0.2% -26.1%

Capital returns

Latest dividend
$0.083 / share · ex Jul 24, 2026
Cut 8.8%
Paid (TTM)
$0.083 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1135951 CUSIP 256135203 13F (30d) 194 filings 184 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)